Thursday, November 19, 2026

Subscribe

NewsEdition DR CongoDR Congo

DR Congo’s Bundibugyo Ebola outbreak outpaces response, prompting vaccine trials

The Democratic Republic of the Congo is facing an unprecedented Bundibugyo Ebola outbreak. The response is under way across Ituri, North Kivu and South Kivu, as vaccine trials become urgent.

A hand holding a smartphone on a street in Kinshasa, with the screen blurred and urban traffic in the background.

An outbreak spreading beyond Ituri province

In the Democratic Republic of the Congo, an epidemic rarely remains confined to a single point on the map. When it strikes the east, it encounters difficult roads, mobile populations, mining areas and health systems under pressure. This combination gives the Bundibugyo Ebola outbreak a particular speed and explains why the response is taking place as much in treatment centres as in communities.

The country is facing its 17th Ebola epidemic since the virus was identified in 1976 in Yambuku, in what is now Équateur province. This new wave was declared on 15 May 2026 by the Congolese authorities, after alerts from Ituri in the north-east, followed by an expansion into North Kivu and South Kivu. The WHO subsequently classified the event as a public health emergency of international concern because of the risk of cross-border spread.

Rising figures, but a cautious reading is needed

The latest consolidated figures published and reported by authoritative sources show rapid growth. As of 15 July 2026, the WHO reported 2,124 confirmed cases in the Democratic Republic of the Congo, including 828 deaths, across 46 health zones in five provinces. The Bundibugyo strain presents a particular challenge: at this stage, there is no licensed vaccine or approved treatment specifically for this variant.

But the situation has evolved further since this mid-July snapshot. On 11 August, government data cited by the Associated Press indicated 4,381 confirmed cases and 2,011 deaths, with the epidemic now described as the fastest-spreading ever observed in terms of transmission. The article also suggested that the outbreak probably began earlier than officially announced, with sequencing indicating that the virus had been circulating as early as February. This gap between the actual start and public declaration partly explains the scale of the outbreak.

Beyond the headline figures, the case fatality rate remains high. The Congolese authorities put it at 45.9% in the recent period cited by several sources, a level that reflects not only the virus’s virulence but also delays in care, difficulties with isolation and limited early access to treatment.

Why the response is struggling to keep pace

In eastern Congo, Ebola never arrives in a vacuum. It adds to insecurity, mistrust, population displacement and social fatigue from repeated emergencies. The WHO and the Congolese authorities have stressed the importance of dialogue with community leaders, women’s associations, young people, religious figures and the private sector. This approach is not merely an added communications measure. It determines access to patients, contact tracing and acceptance of safe and dignified burials, a protocol designed to reduce transmission while respecting families.

The challenge is also logistical and human. In Bunia, response officials said that only 30% of patients were seen in time, while many were dying at home. Other sources have reported attacks on health facilities and field teams, as well as work stoppages linked to unpaid wages. In Ituri, these tensions directly affect contact tracing, community surveillance and trust between the population and public services.

This reality has very tangible effects. In urban areas such as Bunia, fear accelerates the spread of rumours. In rural and mining areas, geographical isolation delays the arrival of response teams. For households, this means late consultations, deaths at home and greater exposure for relatives. For the Congolese state, it means maintaining continuity of routine care, because suspending other health services during the response further weakens residents.

Vaccines, clinical trials and regional reach

In response to the Bundibugyo strain, the scientific response has had to adapt. The WHO recommended evaluating the Ervebo vaccine in a clinical trial. It is already licensed against another type of Ebola, and the trial will assess its usefulness in this context. Doses from the global stockpile supported by Gavi have been mobilised, while other vaccine and treatment candidates have been presented, including by Moderna, Hilleman Laboratories and the University of Oxford. Therapeutic trials have therefore become a central part of the response in the absence of a validated specific solution.

This development has clear regional implications. The Democratic Republic of the Congo shares areas of human movement with Uganda, Rwanda, South Sudan and Tanzania. The WHO has also confirmed cases exported to Uganda, France and Germany, as well as a US patient evacuated for medical care. In other words, an outbreak that began in Ituri quickly becomes a matter for Central Africa and international public health, not just a Congolese crisis.

For Kinshasa, the challenge goes beyond controlling a single epidemic hotspot. It is also a question of demonstrating that the experience gained during previous epidemics can be translated into lasting capacity: laboratories, surveillance, trained staff and regular funding. For the Great Lakes region, the issue is equally political. Health systems are interconnected, borders are porous, and even the slightest delay in coordination costs lives. At continental level, this outbreak is a reminder that a credible African health response must rely on the continent’s institutions, national authorities and research tools capable of acting quickly, together and close to communities.

Automatic translation. Original French version

News quiz

Edition DR CongoDR Congo: the news quiz for 14–15 November

5 questions